Research graph
References from Deep graph embedding for prioritizing synergistic anticancer drug combinations. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.pharmthera.2013.01.016
10.1016/j.pharmthera.2013.01.016 · External reference
10.1038/nrd2683
10.1038/nrd2683 · External reference
10.1016/j.cell.2011.02.013
10.1016/j.cell.2011.02.013 · External reference
An unbiased oncology compound screen to identify novel combination strategies
10.1158/1535-7163.mct-15-0843 · 2016 · External reference
Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
10.3892/or.2016.5315 · 2017 · External reference
10.1172/jci86249
10.1172/jci86249 · External reference
10.1093/bioinformatics/btx806
10.1093/bioinformatics/btx806 · External reference
Combinatorial therapy discovery using mixed integer linear programming
10.1093/bioinformatics/btu046 · 2014 · External reference
Approaches to modernize the combination drug development paradigm
10.1186/s13073-016-0369-x · 2016 · External reference
A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction
2018 · External reference
Methods for high-throughput drug combination screening and synergy scoring
10.1007/978-1-4939-7493-1_17 · 2018 · External reference
10.1093/nar/gkz337
10.1093/nar/gkz337 · External reference
Predicting synergism of cancer drug combinations using NCI-ALMANAC data
10.3389/fchem.2019.00509 · 2019 · External reference
Synergistic drug combination prediction by integrating multi-omics data in deep learning models
2018 · External reference
10.1093/bioinformatics/bty294
10.1093/bioinformatics/bty294 · External reference
The problem of synergism and antagonism of combined drugs
1953 · External reference
STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data
10.1093/nar/gkv1277 · 2015 · External reference
The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible
2016 · External reference
The BioGRID interaction database: 2015 update
10.1093/nar/gku1204 · 2014 · External reference
10.1039/c8sc04228d
10.1039/c8sc04228d · External reference
Graph convolutional networks for computational drug development and discovery
2019 · External reference
Semi-supervised classification with graph convolutional networks
2016 · External reference
Convolutional neural networks on graphs with fast localized spectral filtering
2016 · External reference
10.1023/a:1022627411411
10.1023/a:1022627411411 · External reference
10.1023/a:1010933404324
10.1023/a:1010933404324 · External reference
Regularization and variable selection via the elastic net
10.1111/j.1467-9868.2005.00503.x · 2005 · External reference
10.1016/j.neunet.2014.09.003
10.1016/j.neunet.2014.09.003 · External reference
10.1002/jcc.21707
10.1002/jcc.21707 · External reference
Complex embeddings for simple link prediction
2016 · External reference
Signed graph attention networks
2019 · External reference
A method for stochastic optimization
2014 · External reference
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
2005 · External reference
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
10.18632/oncotarget.21221 · 2017 · External reference
Phase II study of dasatinib in previously treated patients with advanced non-small cell lung cancer
10.1080/07357907.2016.1253710 · 2017 · External reference
Bortezomib-induced lung toxicity
2014 · External reference
Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells
10.1016/j.canlet.2015.02.044 · 2015 · External reference
Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy
10.1158/1078-0432.ccr-09-2882 · 2010 · External reference
Introduction to semi-supervised learning
2009 · External reference
A phase I trial of combined ridaforolimus and MK-2206 in patients with advanced malignancies
10.1158/1078-0432.ccr-15-0180 · 2015 · External reference
Do we need hundreds of classifiers to solve real world classification problems?
2014 · External reference
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
10.1158/1535-7163.mct-10-0792 · 2011 · External reference
A phase I trial of MK-2206 in children with refractory malignancies: a Children’s Oncology Group study
10.1002/pbc.25023 · 2014 · External reference
Mead acid inhibits the growth of KPL-1 human breast cancer cells in vitro and in vivo
10.3892/or.2014.3390 · 2014 · External reference
10.18632/oncotarget.188
10.18632/oncotarget.188 · External reference
For better treatment of triple negative breast cancer
10.3233/bd-2010-0307 · 2010 · External reference
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
2017 · External reference
10.1074/jbc.m110.164046
10.1074/jbc.m110.164046 · External reference
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
10.1016/j.canlet.2015.07.007 · 2015 · External reference
10.3390/cancers11030363
10.3390/cancers11030363 · External reference
Dasatinib inhibits multiple myeloma growth by blocking PDGF-Rb and c-Src activity in patient-derived tumor and endothelial
2007 · External reference
Incorporating bortezomib into the treatment of lung cancer
10.1158/1078-0432.ccr-07-0334 · 2007 · External reference
Phase II study of dasatinib in patients with advanced non–small-cell lung cancer
10.1200/jco.2010.30.5474 · 2010 · External reference
Sensitization of TRAIL–resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin
10.1158/1535-7163.mct-05-0129 · 2006 · External reference
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures
10.1023/a:1011921031564 · 1998 · External reference
10.18632/oncotarget.1706
10.18632/oncotarget.1706 · External reference
The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells
2015 · External reference
A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R–3327G and anabolic activity on skeletal muscle mass & function in castrated mice
10.1016/j.jsbmb.2016.04.007 · 2016 · External reference
